Infliximab biosimilar in patients with IBD

A subcutaneous infliximab biosimilar may be safe and effective in patients with Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease or IBD.

In two phase III trials, published in Gastroenterology, researchers assigned patients with moderate-to-severe IBD to receive the subcutaneous infliximab biosimilar for 10 weeks. Those who responded to treatment were then randomly assigned to receive either 120 mg of the subcutaneous infliximab biosimilar or placebo every two weeks for 54 weeks.

Compared with the patients who received placebo, those who received the subcutaneous infliximab biosimilar had greater clinical remission and endoscopic response rates and experienced no new safety signals.

The researchers concluded that the subcutaneous infliximab biosimilar may be an effective treatment option for maintenance therapy in patients with IBD.

Read more: Gastroenterology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.